AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.67
-0.07 (-2.55%)
At close: 4:00PM EDT

2.71 +0.04 (1.50%)
After hours: 6:47PM EDT

Stock chart is not supported by your current browser
Previous Close2.74
Open2.74
Bid2.65 x 1100
Ask2.71 x 4000
Day's Range2.64 - 2.76
52 Week Range1.86 - 3.59
Volume1,527,162
Avg. Volume2,591,141
Market Cap418.696M
Beta (3Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.32
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
Trade prices are not sourced from all markets
  • Why AVEO Pharmaceuticals, Inc. Stock Perked Up in September
    Motley Fool7 days ago

    Why AVEO Pharmaceuticals, Inc. Stock Perked Up in September

    AVEO is close to a key clinical readout that could prove to be a major catalyst for its stock.

  • Do Options Traders Know Something About AVEO Stock We Don't?
    Zacks9 days ago

    Do Options Traders Know Something About AVEO Stock We Don't?

    Investors need to pay close attention to AVEO stock based on the movements in the options market lately.

  • Business Wire9 days ago

    AVEO Oncology to Present Updated Interim Results from the Phase 2 Portion of the TiNivo Study of Tivozanib and Nivolumab (OPDIVO®) in RCC at the ESMO 2018 Annual Congress

    AVEO Oncology (AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. The TiNivo study is a Phase 1b/2 multicenter trial of oral tivozanib (FOTIVDA®) in combination with intravenous nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma (mRCC). The accepted abstract, which includes results from a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January, is available via the ESMO 2018 Annual Congress website.

  • Business Wire17 days ago

    AVEO Oncology Announces Initiation of Topline Analysis of Phase 3 TIVO-3 Trial

    AVEO Oncology (AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3 Study Steering Committee, and after notice to the FDA. The TIVO-3 trial is the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® (tivozanib) to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). The Company expects to complete data analysis and report topline results from the study in approximately 6 weeks.

  • AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 6.4% in Session
    Zacks21 days ago

    AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 6.4% in Session

    AVEO Pharmaceuticals (AVEO) shares rose more than 6% in the last trading session, amid huge volumes.

  • ACCESSWIRE22 days ago

    Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Heron Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...

  • Why AVEO Pharmaceuticals Inc. Rocketed Higher Today
    Motley Fool22 days ago

    Why AVEO Pharmaceuticals Inc. Rocketed Higher Today

    Hint: It had nothing to do with the press release. The biotech is presenting at a few upcoming conferences, but only one really matters.

  • Business Wire23 days ago

    AVEO Oncology to Participate in Upcoming Conferences

    A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.

  • Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
    Zackslast month

    Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

    Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

  • AVEO (AVEO) Up 25.3% Since Last Earnings Report: Can It Continue?
    Zackslast month

    AVEO (AVEO) Up 25.3% Since Last Earnings Report: Can It Continue?

    AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Motley Foollast month

    Here's Why AVEO Pharmaceuticals Inc. Jumped 40% Higher in August

    Investors jump in ahead of expected clinical trial data.

  • Aveo Stock Breaks Out After Strong Drug Results and a Modest Offering
    InvestorPlace2 months ago

    Aveo Stock Breaks Out After Strong Drug Results and a Modest Offering

    When a biotech company prices a common stock offering, diluting existing shareholders, the stock typically falls. Around $11.1 million of its net income is due to a non-cash gain related to the fall in the fair value of the 2016 private placement warrant liability.

  • Business Wire2 months ago

    AVEO Oncology to Participate in Upcoming Conferences

    A live webcast of Mr. Bailey’s presentation at the Rodman & Renshaw conference can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and AVEO Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 27, 2018 / U.S. equities closed up on Friday following Federal Reserve Chairman Jerome Powell's speech, which confirmed the Federal Reserve will gradually normalize monetary ...

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Teradata, Boyd Gaming, Intrepid Potash, MSG Networks, AVEO Pharmaceuticals, and NetScout — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Teradata ...

  • Business Wire2 months ago

    AVEO Announces Pricing of $5.7 Million Public Offering of Common Stock

    AVEO Pharmaceuticals, Inc. (AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018, which would result in aggregate gross proceeds of approximately $5.7 million before underwriting discounts. All of the shares in the offering are to be sold by AVEO. AVEO has also granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of common stock on the same terms and conditions.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Array BioPharma and AVEO Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...

  • Business Wire2 months ago

    AVEO Announces Proposed Offering of Common Stock

    AVEO Pharmaceuticals, Inc. (AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including development and pre-commercial expenses incurred in connection with the ongoing Phase 3 clinical trial of tivozanib in the third-line treatment of patients with advanced renal cell carcinoma (“aRCC”) as well as the ongoing Phase 1b/2 clinical trial of tivozanib in combination with OPDIVO® (nivolumab).

  • Business Wire2 months ago

    AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China

    AVEO Oncology (AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in esophageal squamous cell cancer (ESCC). Under the terms of a March 2016 agreement, the acceptance of this IND triggers a $2 million milestone payment to AVEO from CANbridge Life Sciences. CANbridge licensed worldwide rights, excluding the United States, Canada, and Mexico, to AV-203 from AVEO and AVEO is eligible to receive up to $40 million in potential additional development and regulatory milestone payments and up to $90 million in potential commercial milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives.

  • AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
    Zacks2 months ago

    AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss

    AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.

  • AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates
    Zacks2 months ago

    AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates

    AVEO (AVEO) delivered earnings and revenue surprises of -150.00% and -67.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    AVEO: 2Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had profit of 6 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The results did not meet Wall Street expectations. ...

  • Business Wire2 months ago

    AVEO Reports Second Quarter 2018 Financial Results and Provides Business Update

    AVEO Oncology today reported financial results for the second quarter ended June 30, 2018 and provided a business update.

  • Business Wire3 months ago

    AVEO Oncology to Present at the Canaccord Genuity 38th Annual Growth Conference

    AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.